Cargando…
Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial
BACKGROUND: Patients with type-2 diabetes mellitus (T2DM), have a higher risk of future cardiovascular diseases (CVD). Meanwhile, probiotics are shown to positively impact CVD-related parameters. This randomized controlled trial sought to evaluate the effects of probiotic supplementation on fundamen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006598/ https://www.ncbi.nlm.nih.gov/pubmed/35418091 http://dx.doi.org/10.1186/s13098-022-00822-z |
_version_ | 1784686699133009920 |
---|---|
author | Ahmadian, Fatemeh Razmpoosh, Elham Ejtahed, Hanieh-Sadat Javadi, Maryam Mirmiran, Parvin Azizi, Fereidoun |
author_facet | Ahmadian, Fatemeh Razmpoosh, Elham Ejtahed, Hanieh-Sadat Javadi, Maryam Mirmiran, Parvin Azizi, Fereidoun |
author_sort | Ahmadian, Fatemeh |
collection | PubMed |
description | BACKGROUND: Patients with type-2 diabetes mellitus (T2DM), have a higher risk of future cardiovascular diseases (CVD). Meanwhile, probiotics are shown to positively impact CVD-related parameters. This randomized controlled trial sought to evaluate the effects of probiotic supplementation on fundamental CVD-related parameters including atherogenic index of plasma (AIPs), blood pressure, the Framingham risk score, and antioxidant markers in patients with T2DM. METHODS: Eligible participants were randomly assigned to receive 2 capsules/day of probiotics [each containing 500 mg of L.acidophilus(5 × 10(10) CFU/g), L.plantarum(1.5 × 10(10) CFU/g), L.fermentum(7 × 10(9) CFU/g), L.Gasseri(2 × 10(10) CFU/g) and 38.5 mg of fructo-oligo-saccharides], or placebo for 6 weeks. Systolic and diastolic blood pressures (SBP and DBP, respectively), mean arterial blood pressure (MAP), atherogenic indices (the ratios of TC/HDL-C, LDL-C/HDL-C, and logTG/HDL-C), the 10-year Framingham CVD risk score, as well as total anti-oxidant capacity (TAC), paraoxonase (PON) and total oxidant status (TOS) were evaluated before and after the study. Final analyses were adjusted based on baseline parameters, and potential covariates including age, sex, PUFA and sodium intakes. RESULTS: Sixty participants completed the study. Compared with placebo, probiotic supplementation resulted in a significant decrease in SBP[-9.24 mmHg(− 14.5, − 3.9)], DBP[− 3.71 mmHg(− 6.59, − 0.83)], MAP[− 5.55 mmHg(− 8.8, − 2.31)], the Framingham risk categories [medium–low(1.5) vs. 2 (medium)] and logTG/HDL-C ratio [− 0.08 (− 0.14, 0)] (All P < 0.05) at the end of the study. No significant changes were observed in the antioxidant markers. CONCLUSION: Overall, probiotic supplementation for 6 weeks led to a significant improvement in major CVD-related parameters in populations with T2DM, suggesting the possible beneficial role of probiotics in lowering the risk of future CVDs associated with diabetes. Nevertheless, more studies are needed to confirm the veracity of these results. Trial registration: IRCT2013100714925N1 (registered on November, 9th, 2013). |
format | Online Article Text |
id | pubmed-9006598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90065982022-04-14 Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial Ahmadian, Fatemeh Razmpoosh, Elham Ejtahed, Hanieh-Sadat Javadi, Maryam Mirmiran, Parvin Azizi, Fereidoun Diabetol Metab Syndr Research BACKGROUND: Patients with type-2 diabetes mellitus (T2DM), have a higher risk of future cardiovascular diseases (CVD). Meanwhile, probiotics are shown to positively impact CVD-related parameters. This randomized controlled trial sought to evaluate the effects of probiotic supplementation on fundamental CVD-related parameters including atherogenic index of plasma (AIPs), blood pressure, the Framingham risk score, and antioxidant markers in patients with T2DM. METHODS: Eligible participants were randomly assigned to receive 2 capsules/day of probiotics [each containing 500 mg of L.acidophilus(5 × 10(10) CFU/g), L.plantarum(1.5 × 10(10) CFU/g), L.fermentum(7 × 10(9) CFU/g), L.Gasseri(2 × 10(10) CFU/g) and 38.5 mg of fructo-oligo-saccharides], or placebo for 6 weeks. Systolic and diastolic blood pressures (SBP and DBP, respectively), mean arterial blood pressure (MAP), atherogenic indices (the ratios of TC/HDL-C, LDL-C/HDL-C, and logTG/HDL-C), the 10-year Framingham CVD risk score, as well as total anti-oxidant capacity (TAC), paraoxonase (PON) and total oxidant status (TOS) were evaluated before and after the study. Final analyses were adjusted based on baseline parameters, and potential covariates including age, sex, PUFA and sodium intakes. RESULTS: Sixty participants completed the study. Compared with placebo, probiotic supplementation resulted in a significant decrease in SBP[-9.24 mmHg(− 14.5, − 3.9)], DBP[− 3.71 mmHg(− 6.59, − 0.83)], MAP[− 5.55 mmHg(− 8.8, − 2.31)], the Framingham risk categories [medium–low(1.5) vs. 2 (medium)] and logTG/HDL-C ratio [− 0.08 (− 0.14, 0)] (All P < 0.05) at the end of the study. No significant changes were observed in the antioxidant markers. CONCLUSION: Overall, probiotic supplementation for 6 weeks led to a significant improvement in major CVD-related parameters in populations with T2DM, suggesting the possible beneficial role of probiotics in lowering the risk of future CVDs associated with diabetes. Nevertheless, more studies are needed to confirm the veracity of these results. Trial registration: IRCT2013100714925N1 (registered on November, 9th, 2013). BioMed Central 2022-04-13 /pmc/articles/PMC9006598/ /pubmed/35418091 http://dx.doi.org/10.1186/s13098-022-00822-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ahmadian, Fatemeh Razmpoosh, Elham Ejtahed, Hanieh-Sadat Javadi, Maryam Mirmiran, Parvin Azizi, Fereidoun Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial |
title | Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial |
title_full | Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial |
title_fullStr | Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial |
title_full_unstemmed | Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial |
title_short | Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial |
title_sort | effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006598/ https://www.ncbi.nlm.nih.gov/pubmed/35418091 http://dx.doi.org/10.1186/s13098-022-00822-z |
work_keys_str_mv | AT ahmadianfatemeh effectsofprobioticsupplementationonmajorcardiovascularrelatedparametersinpatientswithtype2diabetesmellitusasecondarydataanalysisofarandomizeddoubleblindcontrolledtrial AT razmpooshelham effectsofprobioticsupplementationonmajorcardiovascularrelatedparametersinpatientswithtype2diabetesmellitusasecondarydataanalysisofarandomizeddoubleblindcontrolledtrial AT ejtahedhaniehsadat effectsofprobioticsupplementationonmajorcardiovascularrelatedparametersinpatientswithtype2diabetesmellitusasecondarydataanalysisofarandomizeddoubleblindcontrolledtrial AT javadimaryam effectsofprobioticsupplementationonmajorcardiovascularrelatedparametersinpatientswithtype2diabetesmellitusasecondarydataanalysisofarandomizeddoubleblindcontrolledtrial AT mirmiranparvin effectsofprobioticsupplementationonmajorcardiovascularrelatedparametersinpatientswithtype2diabetesmellitusasecondarydataanalysisofarandomizeddoubleblindcontrolledtrial AT azizifereidoun effectsofprobioticsupplementationonmajorcardiovascularrelatedparametersinpatientswithtype2diabetesmellitusasecondarydataanalysisofarandomizeddoubleblindcontrolledtrial |